Data are available from the figshare database (DOI: [10.6084/m9.figshare.12369521](https://doi.org/10.6084/m9.figshare.12369521)).

Introduction {#sec005}
============

Every year, approximately 75 million radiocontrast media applications take place worldwide. \[[@pone.0234921.ref001]\] These administrations are associated with a risk to deteriorate renal function, especially in those subjects with preexisting chronic kidney disease (CKD). Contrast-induced acute kidney injury (CI-AKI) is one of the most frequent forms of in-hospital kidney injury. Since there is no available treatment and since even a mild 0.3 mg/dl increase of serum creatinine (AKI stage I) increases in-hospital mortality by 80%, preventive measures like plasma expansion by intravenous volume application are used in subjects at increased risk. \[[@pone.0234921.ref002]\] Risk assessment is traditionally based on the calculation of estimated glomerular filtration rate (eGFR) and albuminuria. For two reasons it may be questioned, whether these markers are the optimal parameters to identify subjects at risk. First, eGFR calculations are imprecise in the range beyond 60 ml/min. Hence, eGFR is unable to detect mild tubular injury. Second, albuminuria is a marker of glomerular injury, not a marker of tubular injury. Contrast media, however, exert their nephrotoxicity at the tubules, both by direct cytotoxic effects and the induction of tubular hypoxia. \[[@pone.0234921.ref003]\]

We therefore hypothesized that urinary biomarkers of tubular injury might serve as alternative biomarkers in the risk assessment of CI-AKI. The present prospective cohort study characterizes the prognostic accuracy of neutrophil gelatinase-associated lipocalin (NGAL) as a marker of distal tubular damage, kidney injury molecule-1 (KIM-1) as a marker of proximal tubular damage, and calprotectin as an inflammatory renal biomarker for the development of CI-AKI in a population of 490 subjects undergoing coronary angiography.

Materials and methods {#sec006}
=====================

Study design and protocol {#sec007}
-------------------------

The present prospective cohort study was conducted at two German university hospitals (Ruhr-University Bochum and Charité --Universitätsmedizin Berlin, Campus Benjamin Franklin). Inclusion criterion was the indication for a coronary angiography. Exclusion criteria were acute hemodynamic shock, obstructive uropathy, urothelial carcinoma, metastatic cancer, and leukocyturia in semiquantitative dipstick examination \> 1. Preexisting CKD was defined according to KDIGO criteria. \[[@pone.0234921.ref004]\] Subjects with an eGFR \< 60 ml/min and/or an albuminuria \> 30 mg/g creatinine were regarded as \"clinically overt kidney disease\". Coronary angiographies were performed via radial or femoral arteries. The volume of contrast media was documented. Preventive plasma expansion was performed according to physicians' clinical assessment. Physicians were blinded for the results of biomarker assessments. Blood and urine was collected 24h before contrast application and intravenous plasma expansion. In order to avoid systemic effects, we used biomarker assessments in the urine. 48 to 72h after coronary angiography a second sample was obtained. eGFR was calculated by means of the MDRD formula at both time points. AKI was defined according to the AKIN criteria. \[[@pone.0234921.ref005]\] We investigated the patients for subclinical renal injury by performing a postprocedural biomarker concentration analysis (NGAL, KIM-1) parallelly to the assessment of serum creatinine. We regarded an increase of NGAL/creatinine or KIM-1/creatinine by \> 100% (2 fold) as subclinical AKI. The study was approved by the local ethics committee of the Ruhr-University Bochum (registry number 4866--13) and the Charité --Universitätsmedizin Berlin (registry number EA4/117/13). The study was conducted according to the principles from the Declaration of Helsinki. All patients provided written informed consent.

Measurement of urinary NGAL, KIM-1 and calprotectin concentrations {#sec008}
------------------------------------------------------------------

Urine samples (10 ml) were collected and stored frozen (-20°C) until measurement of biomarker concentrations took place. Urinary concentration of NGAL (BPD-KIT-036, BioPorto Diagnostics), KIM-1 (ADI-900-226-0001, Enzo Life Science), and calprotectin (PhiCal® Calprotectin, K 6928, Immundiagnostik AG, Bensheim, Germany) were assessed by enzyme-linked immunosorbent assay (ELISA) according to manufacturer's protocol and previous publications. \[[@pone.0234921.ref006], [@pone.0234921.ref007]\] All the ELISA antibodies were used in previous large studies on AKI. Thus, calprotectin and KIM-1 antibodies were successfully used before in adult, pediatric and transplant populations. \[[@pone.0234921.ref006]--[@pone.0234921.ref017]\] The NGAL assay underwent a clinical validation and was used in diverse studies. \[[@pone.0234921.ref018]\] All urinary biomarker concentrations were normalized to urinary creatinine concentration.

Statistical analysis {#sec009}
--------------------

Data were checked for Gaussian distribution (D'Agostino Pearson). Data are presented as median and interquartile range (IQR). Comparison of continuous parameters in subjects with and without CI-AKI was performed by a Mann-Whitney U-test. Categorical parameters were compared by χ^2^ test. The analysis of pre- vs. postprocedural biomarkers was done via Mann-Whitney paired U-test. Receiver-operating characteristic (ROC) curves were formed in an attempt to determine the accuracy of the urinary biomarkers NGAL, KIM-1, and calprotectin in the prediction of CI-AKI, each of them adjusted for urinary creatinine. Areas under the curve (AUC) of each biomarker were compared according to DeLong. \[[@pone.0234921.ref019]\] Optimal cut-off values were calculated by the Youden's index. Positive predictive values and negative predictive values were calculated from sensitivity and specificity of the biomarker within the population. We performed binary logistic regression analysis for each biomarker (urinary NGAL-, KIM-1- and calprotectin/creatinine), as well as a multivariable regression model for CI-AKI involving eGFR, NGAL-, KIM-1-, and calprotectin ratios as predictors. We applied the score based prediction models from Inohara et al. and Ghani et al. to the study population, including NGAL as an additional predictor. \[[@pone.0234921.ref020], [@pone.0234921.ref021]\] P\<0.05 was regarded statistically significant. All statistical analyses were performed using Prism 7 (GraphPad Software, La Jolla, CA, USA) and SPSS Statistics 25 (SPSS Inc., Chicago, IL, USA).

Results {#sec010}
=======

490 subjects (363 male, 127 female) were enrolled in the study and received a follow-up examination at 48-72h post coronary angiography. Median age was 66 (IQR 57--73). 144 (29.3%) patients suffered from pre-existing CKD, comprising 97 females and 47 males with a median age of 73 (IQR 67--78). The average amount of contrast media needed was 80 (IQR 60--120) ml. The epidemiological data are shown in [Table 1](#pone.0234921.t001){ref-type="table"}. Preprocedural assessment of urinary calprotectin and NGAL was successful in the whole study population, KIM-1 failed in one sample. Follow-up urine was obtained in 472 patients. Periprocedural plasma expansion was performed in 120 subjects (24.5%).

10.1371/journal.pone.0234921.t001

###### Study population.

![](pone.0234921.t001){#pone.0234921.t001g}

  --------------------------------------- -------------------------------------- ---------------------- ------------------------- ------------------------ -------------------------- -------------
                                          **Total study population (n = 490)**   **CI-AKI (n = 30)**    **No CI-AKI (n = 460)**   **p**                    **Main comorbidities**     
  **Hypertension**                        **386 (78.8%)**                                                                                                                             
  Female                                  127 (25.9%)                            9 (30%)                108 (23.5%)               0.386                    Diabetes                   126 (25.7%)
  Male                                    363 (74.1%)                            21 (70.0%)             352 (76.5%)               Coronary Heart Disease   323 (65.9%)                
  Age (years)                             66 (57--73)                            70.5 (63--76)          65 (56--73)               **0.013**                **Medication**             
  eGFR (ml/min)                           78.6 (63.4--91.7)                      69.7 (52.9--92.0)      78.8 (63.6--91.8)         0.197                    ACE-I or ARB               367 (74.9%)
  Diuretics                               109 (22.2%)                                                                                                                                 
  eGFR \>60 ml/min                        388 (79.2%)                            20 (66.7%)             369 (80.2%)               0.158                                               
  Mineralocorticoid receptor antagonist   30 (6.1%)                                                                                                                                   
  eGFR 30--60 ml/min                      99 (20.2%)                             10 (33.4%)             88 (19.1%)                                                                    
  eGFR \<30 ml/min                        3 (0.6%)                               0 (0%)                 3 (0.7%)                  Betablockers             344 (70.2%)                
  Preprocedural creatinine                1.0 (0.8--1.1) mg/dl                   1.0 (0.8--1.3) mg/dl   (0.8--1.1) mg/dl          0.414                    Alpha 1 blockers and CCB   131 (26.7%)
  Postprocedural creatinine               1.0 (0.9--1.2) mg/dl                   1.5 (1.2--1.6) mg/dl   1.0 (0.9--1.2) mg/dl      **0.001**                                           
  AKIN stage I                            27 (5.5%)                              27 (90.0%)             \-                                                                            
  AKIN stage II                           3 (0.6%)                               3 (10.0%)              \-                                                                            
  AKIN stage III                          0 (0.0%)                               0 (0.0%)               \-                                                                            
                                          **No overt CKD (n = 346)**             **CI-AKI (n = 15)**    **No CI-AKI (n = 331)**                                                       
  Female                                  80 (23.1%)                             3 (20.0%)              77 (23.3%)                0.999                                               
  Male                                    266 (76.9%)                            12 (80.0%)             254 (76.7%)                                                                   
  Age (years)                             61 (54--70)                            70 (59--72)            61 (54--69)               0.130                                               
  eGFR (ml/min)                           81.9 (75.7--94.5)                      83.4 (66.3--105.2)     81.9 (73.9--94.4)         0.976                                               
  Preprocedural creatinine                0.9 (0.80--1.0) mg/dl                  0.9 (0.8--1.2) mg/dl   0.9 (0.8--1.0) mg/dl      0.759                                               
  Postprocedural creatinine               1.0 (0.80--1.1) mg/dl                  1.3 (1.1--1.5) mg/dl   1.0 (0.8--1.1) mg/dl      **0.001**                                           
  AKIN stage I                            14 (4.1%)                              14 (9.3%)              \-                                                                            
  AKIN stage II                           1 (0.3%)                               1 (0.7%)               \-                                                                            
  AKIN stage III                          0 (0.0%)                               0 (0.0%)               \-                                                                            
  --------------------------------------- -------------------------------------- ---------------------- ------------------------- ------------------------ -------------------------- -------------

CKD--chronic kidney disease. CI-AKI--contrast media induced acute kidney injury. eGFR--estimated glomerular filtration rate. AKIN--acute kidney injury network. ACE-I--angiotensin converting enzyme inhibitor. ARB---angiotensin II receptor blocker. CCB--calcium channel blockers.

CI-AKI occurred in 30 patients (6.1%). 27 (5.5%) AKIs were classified as AKIN stage I, three (0.6%) as AKIN stage II, and none as AKIN stage III ([Table 1](#pone.0234921.t001){ref-type="table"}). The median urinary NGAL/creatinine ratios of patients suffering from CI-AKI (60.8 \[IQR 18.7--93.1\] μg/mg) were significantly higher than those without CI-AKI (19.9 \[IQR 12.3--38.9\] μg/mg; p = 0.001). Calprotectin/creatinine ratios showed no significant difference in the two groups (175.8 \[IQR 24.1--807.1\] vs. 102.2 \[IQR 25.7--453.9\] ng/mg; p = 0.523). Analogously, KIM-1/creatinine ratios did not differ between these groups (1249.0 \[IQR 616.6--2502.0\] vs. 1056.0 \[IQR 700.7--1601.0\] pg/mg; p = 0.145). An overview of the biomarker concentrations is presented in [Table 2](#pone.0234921.t002){ref-type="table"} and [Fig 1](#pone.0234921.g001){ref-type="fig"}. We also saw a postprocedural increment of all three urinary biomarker ratios (NGAL p = 0.005, KIM-1 p = 0.001, calprotectin p = 0.001). In n = 131 subjects postprocedural NGAL/creatinine ratios and in n = 92 KIM-1/creatinine ratios were increased by a factor \> 2 compared to baseline values. The AUC for the prediction of these "subclinical AKIs" were as follows: Baseline NGAL/creatinine AUC 0.66 (95% CI 0.60--0.71), baseline KIM-1 0.55 (95% CI 0.48--0.61).

![Individual urinary biomarker-creatinine ratios of subjects with and without contrast media induced acute kidney injury (CI-AKI) after coronary angiography for (A) neutrophil gelatinase-associated lipocalin (NGAL), (B) kidney injury molecule-1 (KIM-1), and (C) calprotectin. Data are presented as scatter plots (logarithmic Y-axis, medians and interquartile ranges are indicated by horizontal lines). Significant differences were \*\*\*p\<0.001, \*\*p\<0.01 and \*p\<0.05 by Mann-Whitney testing.](pone.0234921.g001){#pone.0234921.g001}

10.1371/journal.pone.0234921.t002

###### Predictive value of urinary biomarkers for contrast media induced acute kidney injury (CI-AKI).

![](pone.0234921.t002){#pone.0234921.t002g}

                              CI-AKI                   No CI-AKI                p           Sensitivity   Specificity   Positive predictive value   Negative predictive value
  --------------------------- ------------------------ ------------------------ ----------- ------------- ------------- --------------------------- ---------------------------
  Study population            30 (6.1%)                460 (93.9%)                                                                                  
  NGAL (μg/mg crea)           60.8 (18.7--93.1)        19.9 (12.3--38.9)        **0.001**   82.6%         53.3%         16.7%                       96.5%
  Calprotectin (ng/mg crea)   175.8 (24.1--807.1)      102.2 (25.7--453.9)      0.52        90.0%         23.3%         13.7%                       94.7%
  KIM-1 (pg/mg crea)          1249.0 (616.6--2502.0)   1056.0 (700.7--1601.0)   0.15        82.8%         43.3%         12.8%                       95.7%

Neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), and calprotectin in the prediction of contrast media induced acute kidney injury (CI-AKI). All urinary biomarkers are presented after normalization for urine creatinine concentration (crea). Numeric data is presented as median with interquartile range (in brackets). P \<0.05 is considered statistically significant.

In the subgroup of patients, who did not have pre-existing CKD (n = 346), CI-AKI occurred in 15 patients. The severity of CI-AKI was mild (14 AKIN I, 1 case of AKIN II). Median eGFR of these 346 patients was 81.9 (IQR 73.7--94.5) ml/min with a median ACR of 4.2 (IQR 2.7--7.8) mg/g creatinine. NGAL/creatinine ratios were 2.6 fold higher in those subjects, who later developed CI-AKI (47.8 \[IQR 11.8--75.3\] vs. 18.6 \[IQR 11.7--36.3\] μg/mg), but failed to reach significance (AUC 0.63 \[95% CI 0.46--0.79\]; p = 0.102). The urinary creatinine ratios of KIM-1 (867.5 \[IQR 509.7--1466\] vs. 989.1 \[IQR 636--1445\] pg/mg; p = 0.703) and calprotectin (55.5 \[IQR 9.4--634.4\] vs. 90.9 \[IQR 21.4--399\] ng/mg; p = 0.576) were similar in both groups. The results of the biomarker analyses are presented in [Fig 2](#pone.0234921.g002){ref-type="fig"}. Postprocedural urinary analysis revealed an increase of all biomarkers (NGAL p = 0.015, KIM-1 p = 0.001, Calprotectin p = 0.032). 95 and 57 patients showed an increase of NGAL/creatinine and KIM-1/creatinine by 100%, respectively. The calculated AUC in ROC analysis were 0.67 (95% CI 0.61--0.74) for NGAL/creatinine and 0.54 (95% CI 0.48--0.61) for KIM-1/creatinine ratios.

![Individual urinary biomarker-creatinine ratios of subjects with and without contrast media induced acute kidney injury (CI-AKI) after coronary angiography in the subgroup of patients without clinically overt kidney disease (eGFR \> 60 ml, ACR \> 30 mg/g creatinine; left column).\
Analyses are presented for (A) neutrophil gelatinase-associated lipocalin (NGAL), (B) kidney injury molecule-1 (KIM-1), and (C) calprotectin. Data are presented as scatter plots (logarithmic Y-axis, medians and interquartile ranges are indicated by horizontal lines). Significant differences were \*\*\*p\<0.001, \*\*p\<0.01 and \*p\<0.05 by Mann-Whitney testing.](pone.0234921.g002){#pone.0234921.g002}

The prognostic accuracy of NGAL-, KIM-1- and calprotectin/creatinine ratios were analysed by ROC analyses and displayed in [Fig 3](#pone.0234921.g003){ref-type="fig"}. Univariate regression analysis was significant for NGAL only (p = 0.005), yielding the highest prognostic accuracy with an AUC of 0.68 (95% CI 0.60--0.81). The AUC of KIM-1 and calprotectin were 0.58 (95% CI 0.46--0.70) and 0.54 (95% CI 0.42--0.65). The pairwise comparison of urinary NGAL- and calprotectin/creatinine AUCs showed a significant difference (p = 0.009). The AUC of the regression model plotting NGAL, KIM-1, calprotectin ratios as well as eGFR was 0.68 (95% CI 0.60--0.81; [S1 Table](#pone.0234921.s001){ref-type="supplementary-material"}). [Table 2](#pone.0234921.t002){ref-type="table"} presents the prognostic accuracy of each parameter using the optimal cut-off values obtained by Youden's index (*J* = sensitivity + specificity---1). NGAL (56.4 μg/mg creatinine; *J* = 0.360) revealed 82.6% sensitivity, 53.3% specificity, 16.7% positive predictive value (PPV), and 96.5% negative predictive value (NPV). In the subgroup of patients without CKD, the predictors NGAL-, KIM-1- and calprotectin/creatinine failed to reach individual significance in the regression analysis, the multivariable model yielded an AUC of 0.62 (95% CI 0.46--0.77; [S1 Table](#pone.0234921.s001){ref-type="supplementary-material"}).

![Accuracy of biomarker-creatinine ratios of (A) urinary neutrophil gelatinase-associated lipocalin (NGAL, blue), kidney injury molecule-1 (KIM-1, red) and calprotectin (green) in the prediction of contrast media induced acute kidney injury (CI-AKI) after coronary angiography in receiver operating characteristic (ROC) analysis. The predictive accuracy for CI-AKI in the present study population following the models of Ghani et al. (blue) and Inohara et al. (green) is displayed in (B). ROC curves adding NGAL/creatinine as predictor into the model are displayed in red and black, respectively. AUC--area under the curve. Diagonal scattered lines indicate prediction of CI-AKI by chance.](pone.0234921.g003){#pone.0234921.g003}

Applying the two external CI-AKI prediction models from Inohara et al. and Ghani et al. to the present study group, led to an AUC of 0.68 (95% CI 0.60--0.76) and 0.57 (95% CI 0.46--0.67), respectively. There was a significant increase of the AUC in the Ghani model (0.69 \[95% CI 0.58--0.80\]; p = 0.045), when adding NGAL/creatinine as an additional predictor, whereas in case of the Inohara model, there was still a tendency of amelioration (0.73 \[95% CI 0.63--0.82\], p = 0.085).

Discussion {#sec011}
==========

The present work constitutes the largest prospective study investigating the predictive value of urinary biomarkers in the risk stratification of CI-AKI so far. Whereas NGAL and KIM-1 have been investigated in this context in smaller studies before, calprotectin was examined for the first time. \[[@pone.0234921.ref022]--[@pone.0234921.ref024]\] Since these biomarkers are able to detect subclinical tubular injury, it appeared reasonable that they could contribute to the risk assessment of CI-AKI, especially in those subjects without clinically overt CKD. Indeed, urinary NGAL/creatinine ratios were 3.1 times and thereby significantly higher in those subjects, who later developed CI-AKI.

NGAL served as a marker of distal tubular injury in the present study. It has been repeatedly described as an early diagnostic marker after contrast application, but data on its predictive value for CI-AKI is available only from a few very small trials with conflicting results. \[[@pone.0234921.ref022]--[@pone.0234921.ref024]\] In the present study it proved the best prognostic accuracy of the investigated urinary biomarkers with a high negative predictive value. Thus, an NGAL/creatinine concentration \< 56.4 μg/mg precludes the occurrence of CI-AKI with a 96.5% probability.

KIM-1 was included in the study as a marker of proximal tubular injury. In analogy to NGAL it was demonstrated, that KIM-1 can be a useful diagnostic tool for an early detection of CI-AKI. \[[@pone.0234921.ref023]\] There are no data, however, on a predictive value. The present findings show that KIM-1 is not useful for risk stratification before contrast media application. Urinary calprotectin, a danger associated molecular pattern protein of the innate immune system, mirrors the inflammatory reaction after tubular injury and is thereby able to differentiate subjects with prerenal and intrinsic tubular injury. \[[@pone.0234921.ref006], [@pone.0234921.ref008], [@pone.0234921.ref009], [@pone.0234921.ref025]\] Moreover, calprotectin plays a key role in CI-AKI by activation of toll-like receptor 4. \[[@pone.0234921.ref026]\] In analogy to KIM-1, however, it does not predict tubular injury after contrast application in the present study. Urinary calprotectin levels do not only reflect renal inflammation but are substantially increased in leukocyturia, e. g. in urinary tract infection. In the present population, 14.7% were tested positive for leukocyturia in dip-stick examination, which might partially explain the lacking prognostic value.

Beyond the biomarker investigations, the present study shows once more that the risk of CI-AKI is substantially lower than reported in the past. Only 6.1% of the overall population and 10.4% of the CKD population fulfilled the criteria of an AKI, the majority corresponding to AKIN stage I. There was no severe CI-AKI corresponding to AKIN stage III. A decade ago, the Oxilan Registry described a CI-AKI incidence of 10.5% after radiocontrast media application. \[[@pone.0234921.ref027]\] In analogy with our findings, the incidences in the recent PRESERVE and AMACING trials were rather low (4.4, 4.7% and 2.6, 2.7%, respectively). \[[@pone.0234921.ref028], [@pone.0234921.ref029]\] Less toxic contrast media, less amounts of contrast media during angiography, and a more frequent use of preventive measures may be reasons for the decreasing incidence. Nevertheless, despite any effort to reduce tubular toxicity, we detected a substantial increase in all biomarkers after the application of contrast media, which may be regarded as subclinical tubular injury. The clinical relevance of this tubular injury remains elusive.

The design of the present study aimed at an improvement of the current risk stratification with its subsequent preventive strategies. Therefore, the study design did not influence periprocedural fluid administration, which was performed according to clinical standards with the physicians being blinded for urinary biomarkers. The study thereby inevitably comprised subjects with and without preventive plasma expansion, which, nevertheless constitutes a limitation. On the other hand, it has to be kept in mind that the AMACING study did not show any benefit of saline application at all. \[[@pone.0234921.ref028]\]

Current guidelines still recommend plasma expansion for subjects with clinically manifest CKD. \[[@pone.0234921.ref030]\] In those subjects without albuminuria \> 30mg/g creatinine or an eGFR \< 60 ml/min, urinary NGAL/creatinine ratios provide additional prognostic information. They were 2.6 fold higher in those subjects, who developed CI-AKI later on, noteworthy, without reaching statistical significance. Hence, a subclinical tubular injury is indeed associated with an increased vulnerability for contrast media-induced kidney injury. Thus, NGAL has a prognostic value both in presence and absence of clinically overt renal disease. Published predictive models for CI-AKI are not excelling and show conflicting results in external validation studies. \[[@pone.0234921.ref031], [@pone.0234921.ref032]\] An interesting common aspect is the high NPV, as seen in our study. We applied two scored based models and saw an increment in AUC by including urinary NGAL/creatinine ratios. Further trials, implementing renal biomarkers into common predictive models for CI-AKI, are needed.

There is certainly no reason to measure urinary NGAL concentrations in the overall population prior to application of contrast media. In individual critical clinical scenarios, however, the high negative predictive value of a NGAL/creatinine ratio \< 56.4 μg/mg might indeed be helpful to decide for or against the use of contrast media.

The present study shows that NGAL but not KIM-1 or calprotectin provide prognostic information for the occurrence of AKI after contrast media administration. The high negative predictive value of a urinary NGAL/creatinine ratio \< 56.4 μg/mg may be a clinically relevant information beyond the traditional risk stratification biomarkers eGFR and proteinuria.

Supporting information {#sec012}
======================

###### Univariate and multivariable logistic regression model for CI-AKI.

Univariate logistic regression for CI-AKI using the biomarkers urinary NGAL-, KIM-1- and calprotectin/creatinine as predictors in the overall study population and in the subgroup of subjects without overt CKD. The area under the curve (AUC) represents the discriminatory accuracy of each biomarker, as well as the concordance statistic for the regression model using eGFR, NGAL-, KIM-1- and calprotectin/creatinine ratios as independent variables. Moreover, the predictive value of the models of Inohara et al. and Ghani et al. are presented with and without including NGAL/creatinine ratio into the model.
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Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The following points should be clarified:

\- There is disconcordance between Result section and Tables. The sample has male or female predominance?

\- What is the reason for urinary analysis of the markers in stead of blood sample?

\- Please provide pre-procedural and post-precudural creatinine level.

\- Regression analysis should be explaned with a table.

\- Please provide the amount of contrast amount.

\- Previous studies reported the usefullness of early post-precudural NGAL level. Do you think that, only preprocudural analysis would be enough?

\- Classical AKI defined as 0.5 mg/dl increament in the Cr level. What is the reason for prefer 0.3 mg/dl instead of 0.5.

\- The percentage of AKI is relatively lower although 0.3 mg/dl increament was proposed for AKI patients. What would be the AKI rate according to classical 0.5 mg/dl increament in serum Cr

\- What would be the reason for the neutral effects of KIM-1 and calprotectin in the prediction of AKI

Reviewer \#2: This is a nicely designed cohort study and used several novel biomarkers including KIM-1, NGAL and calprotectin to predict the risk of CI-AKI.

Some concerns need to be clarified.

1\. There are numerous established predictive models for CI-AKI and some of them had pretty good predictive ability. The author may consider to provide the incremental value (i.e., the increase in AUROC, the integrated discrimination index, etc.) of each biomarker over the existing CI-AKI prediction models. Based on this, it will better illustrate the role of these new biomarkers in some clinical circumstances. In fact, the number of CI-AKI events are only 30, it will be limited to perform some rigorous statistical analyses. However, it is recommended for the authors to make some effort on this.

2\. Did the author have post-coronary angiography urine or blood sample for the new biomarkers? I think it would be very interesting to show the proportion of patients with an elevated biomarker (compared with baseline) versus the proportion of those with an elevated creatinine.

Your definition of CI-AKI is based on the KDIGO AKi staging, however, it will be better to show that how many people might have a subclinical structural AKI (elevated biomarker, no elevated creatinine), and maybe another with only functional AKI (elevated creatinine, with normal biomarker).

Materials and methods

Statistical analysis

1\. Since the statistical method of receiver operating characteristics (ROC) was used for discrimination or diagnosis, please replace "prediction" with "diagnosis" (or discrimination) and replace "predictive accuracy" with "diagnostic accuracy" throughout the manuscript.

2\. It is unclear for the sentence "multiple binary logistic regression testing for CI-AKI in the presence of eGFR, NGAL-, KIM-1-, and calprotectin/creatinine ratios". Do the authors introduced these four parameters into one multivariable model? If so, how was the correlation (is there a collinearity problem?) among the three markers? The result of multivariable logistic regression model should be provided, maybe in the supplement file.

3\. Please replace "multiple binary logistic regression testing" with "multivariable logistic regression model"

4\. Please clarify which method of significance of AUC was used, such as the DeLong's method.

Results

1\. Provide the 95% confidence interval of AUC throughout the text.

2\. Please directly compare the AUCs among the three markers, the DeLong's test may be appropriate.

Table 1

1\. The structure of Table 1 is complicated and poorly presented. Only five columns are needed: the variable name, the data of total patients, the data of CI-AKI patients, the data of non CI-AKI patients and the p value.

Table 2

1\. Which test (the column with p value) was performed, is that Mann-Whitney U-test? If so, where is the result of multiple binary logistic regression?

2\. Please provide 3 digits value of P value

3\. The PPV/NPV is calculated based on a given prevalence, please clarify how the prevalence is determined. The prevalence value should be based on a population data or at least a large-scale representative study.

Figure and Figure legends

1\. Please give the exact p value with three digits in Figure 1 and Figure 3 for each marker, regardless of the group comparison is significant or not.

2\. Provide the 95% confidence interval of AUC in Figure 2 or its figure legend

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Reviewer \#1: The following points should be clarified:

\- There is disconcordance between Result section and Tables. The sample has male or female predominance?

REPLY: Thank you for drawing our attention to this flaw. Changes have been made in the revised version of the manuscript. There is a predominance of male subjects.

\- What is the reason for urinary analysis of the markers instead of blood sample?

REPLY: Analysing renal biomarkers in the urine is a non-invasive and easy method to perform. The rationale to investigate the urine is to focus on its specific organ: the kidneys. Hence, KIM-1 is highly upregulated in proximal tubular cells following kidney injury and is shed into the lumen. NGAL and calprotectin are molecules of the immune system, which can be detected in the blood for inflammation of any kind in the human body. For instance, patients with SIRS show high NGAL values in plasma, while urinary NGAL seems less affected by the systemic inflammation.\[1\] In other words, the diagnostic accuracy of a renal biomarker is sought to be higher in the urine. There are large studies demonstrating, that urinary NGAL shows a higher diagnostic performance (e.g. sensitivity, specificity, AUC) compared to plasma in the setting of AKI.\[2\] Studies about the investigation of calprotectin in AKI are rare, and have never been performed in the specific setting of CI-AKI before.\[3-6\] On the one hand, systemic inflammation enhances calprotectin production, which is a danger associated molecule pattern protein. On the other hand, it is a measure of local inflammatory activity, that seems to be unaffected by a variety of conditions that result in an elevation of systemic inflammation.\[7, 8\] In summary, it is reasonable for all the investigated biomarkers to be analysed in the urine. We clarified this issue in the modified version of the manuscript.

\- Please provide pre-procedural and post-procedural creatinine level.

REPLY: Pre- and postprocedural creatinine were provided (Table 1) for the overall study population and the subpopulation without overt CKD in the new version of the manuscript as requested.

\- Regression analysis should be explained with a table.

REPLY: A detailed table about the results of the binary logistic regression has been added to the manuscript (Supplements Table 1).

\- Please provide the amount of contrast amount.

REPLY: The median amount of the contrast media has been implemented in the Results, not only for the overall population, but for the subpopulation without overt CKD as well.

\- Previous studies reported the usefulness of early post-procedural NGAL level. Do you think that, only preprocedural analysis would be enough?

REPLY: We focussed on preprocedural analysis, since the biomarker examination intended the opportunity to identify subjects, who might benefit from periprocedural preventive measures (prognostic value). Post-procedural investigations of the biomarkers are indeed useful to detect subclinical AKI. We decided for the robust primary endpoint of clinically manifest AKI. Neverthess, we additionally provide postprocedural biomarker concentrations in the revised version of the manuscript.

\- Classical AKI defined as 0.5 mg/dl increment in the Cr level. What is the reason for prefer 0.3 mg/dl instead of 0.5.

REPLY: The definition of acute kidney injury is beyond any doubt an important aspect of the study. The reviewer probably refers to the definition acute renal failure (ARF) according to the Risk/Injury/Failure/Loss/End-stage (RIFLE) criteria. The sensitivity and accuracy of the RIFLE compared to AKIN criteria for acute kidney injury (AKI) remains uncertain.\[9\] In our study, we decided to follow the international recognized KDIGO 2012 guidelines, which use AKIN criteria for the definition and the classification of AKI.\[10\] Moreover, RIFLE criteria are defined as changes within 7 days, while the AKIN criteria suggest using 48 hours, which is a better fit to our study design.

\- The percentage of AKI is relatively lower although 0.3 mg/dl increment was proposed for AKI patients. What would be the AKI rate according to classical 0.5 mg/dl increment in serum Cr

REPLY: Using a 0.5 mg/dl increment in serum creatinine as a definition, we would face a lower incidence of AKI (n=8). We described this aspect in the modified version of the manuscript.. As described in Material and Methods and elucidated in the previous question, we primarily followed the international recognized guidelines KDIGO 2012 and defined an AKI according to the AKIN criteria.\[10\]

\- What would be the reason for the neutral effects of KIM-1 and calprotectin in the prediction of AKI.

REPLY: This is indeed an interesting fact, for which there is no clear explanation yet. KIM-1 is a tubular marker like NGAL, although it is expressed at a different location in the nephron. We sought to reflect proximal (KIM-1) and distal (NGAL) tubular damage. It can be speculated, that the difference in-between the renal tubular biomarkers is the result of contrast media toxicity at different levels. Current data suggests, that the deleterious effect of contrast media is more pronounced at the distal tubule, partly due to oxidative stress, impaired tubuloglomerular feedback and increasing viscosity along the tubule.\[11, 12\] Noteworthy, however, there is a non-significant trend for the prediction of CI-AKI by KIM-1. Calprotectin mirrors inflammation, rather than a pre-existing tubular damage. A negative result is plausible.

Reviewer \#2: This is a nicely designed cohort study and used several novel biomarkers including KIM-1, NGAL and calprotectin to predict the risk of CI-AKI.

Some concerns need to be clarified.

1\. There are numerous established predictive models for CI-AKI and some of them had pretty good predictive ability. The author may consider to provide the incremental value (i.e., the increase in AUROC, the integrated discrimination index, etc.) of each biomarker over the existing CI-AKI prediction models. Based on this, it will better illustrate the role of these new biomarkers in some clinical circumstances. In fact, the number of CI-AKI events are only 30, it will be limited to perform some rigorous statistical analyses. However, it is recommended for the authors to make some effort on this.

REPLY: We thank the reviewer for his thoughtful remark and suggestion. The meta-analysis of Allen et al. describes 30 models predicting CI-AKI, from which 9 studies only used preprocedural variables, analogously to our study design.\[13\] Noteworthy, including postprocedural information (remaining 21 studies) did not significantly augment the discriminatory power. There is a considerable amount of heterogeneity amongst the trials, and definition of CI-AKI is not homogenous either. The AUC of NGAL/creatinine (0.68 (95% CI 0.60 - 0.81\]) in our work is lower than the c-statistic of the 9 trials, mentioned above, ranging from 0.71 (95% CI 0.71 -- 0.72) to 0.88 (95% CI 0.85 -- 0.91). However, there was an insufficient external validation for these models. Interestingly, there is a considerable discriminating ability to identify "true-negative" cases (high NPV), as we have seen in our study. The most recent study about CI-AKI prediction model is only a few days old and applies 17 risk prediction models for CI-AKI.\[14\] We chose 2 different prediction models with preprocedural variables only, fitting the available data. NGAL showed an increase in AUC for both models, which was significant by the DeLong comparison method for the Ghani et al. model. The manuscript has been changed accordingly.

2\. Did the author have post-coronary angiography urine or blood sample for the new biomarkers? I think it would be very interesting to show the proportion of patients with an elevated biomarker (compared with baseline) versus the proportion of those with an elevated creatinine.

Your definition of CI-AKI is based on the KDIGO AKI staging, however, it will be better to show that how many people might have a subclinical structural AKI (elevated biomarker, no elevated creatinine), and maybe another with only functional AKI (elevated creatinine, with normal biomarker).

REPLY: The reviewer addresses the interesting aspect of subclinical renal injury post contrast media and we, therefore, have analysed postprocedural urine of this study population. One possibility to assess the presence of renal damage is to follow the cardiac surgery-associated NGAL score (CSA-NGAL score), where NGAL levels \>100 ng/mL suggest a renal tubular damage, however there is no data about the NGAL/ creatinine ratio.\[15\] We therefore defined an elevation of NGAL/creatinine by 100% (2 fold) as subclinical tubular injury, and detected 131 subclinical kidney injuries. We performed the same procedure for KIM-1. Since calprotectin is no marker or tubular damage itself, we refrained from this analysis.

Materials and methods

Statistical analysis

1\. Since the statistical method of receiver operating characteristics (ROC) was used for discrimination or diagnosis, please replace "prediction" with "diagnosis" (or discrimination) and replace "predictive accuracy" with "diagnostic accuracy" throughout the manuscript.

REPLY: We thank the reviewer for his remark. ROC analysis is indeed traditionally used to describe diagnostic accuracy. It is possible, however, to test prognostic accuracy as well.\[16, 17\] The present study's goal was not to diagnose a CI-AKI, but to predict a potential loss of renal function due to contrast media application. In other words, we did not analyse renal biomarkers after the application of contrast media, but before the procedure was done. We offer changing the words according to the suggestion of the reviewer, but are afraid that this might be misleading for some readers and would therefore prefer to keep the word "prediction".

2\. It is unclear for the sentence "multiple binary logistic regression testing for CI-AKI in the presence of eGFR, NGAL-, KIM-1-, and calprotectin/creatinine ratios". Do the authors introduced these four parameters into one multivariable model? If so, how was the correlation (is there a collinearity problem?) among the three markers? The result of multivariable logistic regression model should be provided, maybe in the supplement file.

REPLY: All four parameters have been integrated into a single multivariable model. The Pearson correlation in-between the parameters is low (\<0.5 each, e.g. NGAL/creatinine & eGFR 0.104, KIM-1/creatinine & NGAL/creatinine 0.262, calprotectin/creatinine & KIM-1/creatinine 0.142). We added this information to the manuscript.

3\. Please replace "multiple binary logistic regression testing" with "multivariable logistic regression model"

REPLY: We thank the reviewer for this remark. The manuscript has been changed accordingly.

4\. Please clarify which method of significance of AUC was used, such as the DeLong's method.

REPLY: We used the DeLong method and mentioned this in the revised version of the manuscript.\[18\]

Results

1\. Provide the 95% confidence interval of AUC throughout the text.

REPLY: Changes have been made throughout the manuscript according to the reviewers remarks.

2\. Please directly compare the AUCs among the three markers, the DeLong's test may be appropriate.

REPLY: The comparison of the AUCs by ROC were calculated according to the DeLong et al.\[18\] Only the pairwise comparison of ROC curves from NGAL/creatinine and calprotectin/creatinine became significant with p=0.009. The other pairings (KIM-1/creatinine & NGAL/creatinine and KIM-1/creatinine & calprotectin/creatinine) did not show any relevant differences in AUC (p=0.181 and p=0.577). The manuscript has been changed accordingly.

Table 1

1\. The structure of Table 1 is complicated and poorly presented. Only five columns are needed: the variable name, the data of total patients, the data of CI-AKI patients, the data of non CI-AKI patients and the p value.

REPLY: Table 1 has been redesigned according to the reviewers remarks.

Table 2

1\. Which test (the column with p value) was performed, is that Mann-Whitney U-test? If so, where is the result of multiple binary logistic regression?

REPLY: As described in Material and Methods, comparison of continuous parameters in subjects with and without CI-AKI was performed by Mann Whitney U-test. The results of the regression model is presented in the supplement section.

2\. Please provide 3 digits value of P value

REPLY: Changes have been made throughout the manuscript according to the reviewers remarks.

3\. The PPV/NPV is calculated based on a given prevalence, please clarify how the prevalence is determined. The prevalence value should be based on a population data or at least a large-scale representative study.

REPLY: We have been made to the manuscript. PPV and NPV calculations are based on the sensitivity and specificity of the analysed biomarker within the population. We chose the cut-off value using the Youden index.

Figure and Figure legends

1\. Please give the exact p value with three digits in Figure 1 and Figure 3 for each marker, regardless of the group comparison is significant or not.

REPLY: Changes have been made to the two figures according to the reviewer's remarks.

2\. Provide the 95% confidence interval of AUC in Figure 2 or its figure legend

REPLY: Changes have been made to Figure 2 according to the reviewer's remarks.
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